Literature DB >> 12825200

Contribution of the rev gene to the immunogenicity of DNA vaccines targeting the envelope glycoprotein of HIV.

Nao Jounai1, Kenji Okuda, Yoshitsugu Kojima, Yoshihiko Toda, Kenji Hamajima, Kenji Ohba, Dennis Klinman, Ke-Qin Xin.   

Abstract

BACKGROUND: The Rev protein of HIV plays a critical role in the export of viral mRNA from the nucleus to the cytoplasm of infected cells. This work examines the effect of introducing rev into a DNA vaccine encoding the Env protein of HIV, and compares the activity of env genes regulated by CMV versus CAG promoters.
METHODS: The HIV Env gp160 encoding gene with or without the rev gene was subcloned into a CMV promoter or a CAG promoter-driven expression plasmid. The Env protein expression of the plasmids was examined in vitro and the HIV-specific immunity was explored in BALB/c mice by an intramuscular route. The immune mice were intraperitoneally challenged with an HIV Env-expression vaccinia virus.
RESULTS: Results indicate that the CAG promoter induces significantly higher levels of Env expression, and better immune responses, than the CMV promoter. Incorporating the rev gene into these plasmids further boosts antigen expression and immunogenicity. Indeed, vaccination with the pCAGrev/env or pCMVrev/env plasmid resulted in 1000-fold lower viral load than that with pCMVenv when the mice were challenged with an Env-expressing vaccinia virus.
CONCLUSIONS: Incorporating rev into a DNA vaccine significantly increases the level of expression and immunogenicity of a co-expressed env gene, and that protective efficacy is further improved by utilizing a pCAG promoter. Copyright 2003 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12825200     DOI: 10.1002/jgm.391

Source DB:  PubMed          Journal:  J Gene Med        ISSN: 1099-498X            Impact factor:   4.565


  6 in total

1.  Induction of robust immune responses against human immunodeficiency virus is supported by the inherent tropism of adeno-associated virus type 5 for dendritic cells.

Authors:  Ke-Qin Xin; Hiroaki Mizukami; Masashi Urabe; Yoshihiko Toda; Kaori Shinoda; Atsushi Yoshida; Kenji Oomura; Yoshitsugu Kojima; Motohide Ichino; Dennis Klinman; Keiya Ozawa; Kenji Okuda
Journal:  J Virol       Date:  2006-09-27       Impact factor: 5.103

Review 2.  HIV vaccines: progress to date.

Authors:  C Mee Ling Munier; Christopher R Andersen; Anthony D Kelleher
Journal:  Drugs       Date:  2011-03-05       Impact factor: 9.546

3.  Adenovirus type 5 with modified hexons induces robust transgene-specific immune responses in mice with pre-existing immunity against adenovirus type 5.

Authors:  Shinya Abe; Kenji Okuda; Takehiro Ura; Asami Kondo; Atsushi Yoshida; Shinji Yoshizaki; Hiroyuki Mizuguchi; Dennis Klinman; Masaru Shimada
Journal:  J Gene Med       Date:  2009-07       Impact factor: 4.565

4.  Optimization of lentiviral vector production using polyethylenimine-mediated transfection.

Authors:  Yong Tang; Kenneth Garson; Li Li; Barbara C Vanderhyden
Journal:  Oncol Lett       Date:  2014-11-07       Impact factor: 2.967

Review 5.  Recent Developments in Preclinical DNA Vaccination.

Authors:  Kenji Okuda; Yoshiyuki Wada; Masaru Shimada
Journal:  Vaccines (Basel)       Date:  2014-01-13

6.  A recombinant adenovirus-based vector elicits a specific humoral immune response against the V3 loop of HIV-1 gp120 in mice through the "Antigen Capsid-Incorporation" strategy.

Authors:  Linlin Gu; Valentina Krendelchtchikova; Alexandre Krendelchtchikov; Robert A Oster; Kohtaro Fujihashi; Qiana L Matthews
Journal:  Virol J       Date:  2014-06-16       Impact factor: 4.099

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.